



Wyoming
Department
of Health

Division of Healthcare Financing

Medicaid Pharmacy News

Dear Providers and Pharmacies:

August 17, 2022

PRODUCT SPECIFIC DISPENSING UPDATES

Paxlovid

Effective 8/17/2022, Paxlovid will no longer require a prior authorization through the Medicaid clinical team. Verification for therapeutic appropriateness and accurate billing is still expected using the pharmacist's clinical judgment.

Cabergoline

Within the next few weeks, an update will be deployed to allow cabergoline to be billed for up to a 56 day supply to accommodate prescriptions dosed once weekly and original container labeling. Please continue to dispense cabergoline in its original container and calculate the accurate days' supply for each prescription.

Dexmethylphenidate Products

Effective 8/17/2022, the total maximum daily dose for dexmethylphenidate products will be updated to comply with FDA recommended limits at 45mg for members \leq 13 years of age. Any combination of products (i.e. Focalin XR, dexmethylphenidate IR tablets) will be calculated against the accumulated dose, and will be subject to this therapy limit. For additional information, please refer to the current PDL and Dose Limitation Chart.

For any questions regarding these updates or other policies, the Change Healthcare help desk can be contacted at
877-209-1264.